On Nov. 3, 2020, Humanigen announced the execution of its first licensing transaction in the Asia-Pacific Region with Telcon RF Pharmaceutical and KPM Tech Co., for development and commercialization rights to lenzilumab for COVID-19 for South Korea and the Philippines.

The licensing agreement included payments of up to $20 million with $6 million as an upfront payment upon execution of the licensing agreement and the balance of $14 million in two payments based on achievement by Humanigen of specified milestones in the US.